ClinicalTrials.gg
CompletedNCT07444424Updated Jul 13, 2026

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants

A Phase 1 interventional study of AZD5004 and Mitiglinide in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Enrollment
15th of 18
32 · median 57
Started
2026
with 8 others
Phase 1
11 of 18
none open now
Registered
10th of 18
by date
Lead sponsor
14 of 18
AstraZeneca

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 9 that started in 2026, is one of 11 in phase 1, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to assess the effect of AZD5004 on the pharmacokinetics (PK) of mitiglinide and pioglitazone in healthy participants.

Read the detailed description

This is an open-label, fixed-sequence, two-part study of mitiglinide (Part A) and pioglitazone (Part B) in healthy participants. Part A will assess the PK of mitiglinide when administered alone and in combination with AZD5004 while Part B will assess the PK of pioglitazone when administered alone and in combination of AZD5004.

Both parts are independent and non-sequential to each other.

Each study part will comprise of:

  1. A screening period of maximum 28 days.
  2. Four sequential treatment periods during which the participants will receive the study interventions.
  3. A final follow-up visit
03

Conditions studied

  • Healthy Participants

Keywords

  • Pharmacokinetics
  • Type 2 Diabetes
  • Obesity
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with suitable veins for cannulation or repeated venipuncture.
  • All females must have a negative serum pregnancy test at the Screening Visit and on admission to the study site.
  • Females of must agree to use a highly effective method from enrollment.
  • Male Participants, if heterosexually active, must practice true abstinence or use condoms during the trial and their female partners of childbearing potential must use additional effective contraception during the trial.
  • (BMI) between 18 and 35 kg/m² and weigh at least 50 kg.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which may put the participant at risk or influence the results, including:

    1. Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper gastrointestinal (GI) tract
    2. Cardiovascular disease
    3. Neuromuscular or neurogenic disease
    4. Type 1 or type 2 diabetes mellitus
  • History of acute pancreatitis, chronic pancreatitis, gallstones, or elevation in serum lipase/pancreatic amylase.
  • History of clinically significant cardiovascular, dermatological, respiratory, neurological, psychiatric or GI disease disorder.
  • History of malignant neoplastic disease.
  • History or presence of GI disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma.
  • Any clinically important abnormalities in clinical chemistry, hematology, coagulation, or urinalysis results.
  • Basal calcitonin level ≥ 35 ng/L or history/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2).
  • Uncontrolled thyroid disease.
  • Any positive result on screening for serum (HIV).
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity to drugs with a similar chemical structure or class to AZD5004, or to mitiglinide and/or pioglitazone.
  • Participants who have previously received AZD5004.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Part A: Mitiglinide + AZD5004

    In Period 1, participants receive a single dose of mitiglinide on Day 1, followed by single doses of AZD5004 Dose A once daily from Days 3-9, then single doses of AZD5004 Dose B once daily from Days 10-16. In Period 2, participants receive single dose of mitiglinide co-administered with single dose of AZD5004 Dose B on Day 17, followed by a single dose of AZD5004 Dose B on Day 18, then single doses of AZD5004 Dose C once daily from Days 19-25, followed by single doses of AZD5004 Dose D once daily from Days 26-32. In Period 3, participants receive single dose of mitiglinide co-administered with single dose of AZD5004 Dose D on Day 33, followed by a single dose of AZD5004 Dose D on Day 34, then single doses of AZD5004 Dose E once daily from Days 35-41. In Period 4, participants receive single dose of mitiglinide co-administered with single dose of AZD5004 Dose E on Day 42, followed by a single dose of AZD5004 Dose E on Day 43.

    Drug: AZD5004 · Drug: Mitiglinide

  • Experimental
    Part B: Pioglitazone + AZD5004

    In Period 1, participants receive a single dose of pioglitazone on Day 1, followed by single doses of AZD5004 Dose A once daily from Days 8-14, then single doses of AZD5004 Dose B once daily from Days 15-21. In Period 2, participants receive single dose of pioglitazone co-administered with single dose of AZD5004 Dose B on Day 22, followed by single doses of AZD5004 Dose B once daily from Days 23-28, then single doses of AZD5004 Dose C once daily from Days 29-35, followed by single doses of AZD5004 Dose D once daily from Days 36-42. In Period 3, participants receive single dose of pioglitazone co-administered with single dose of AZD5004 Dose D on Day 43, followed by single doses of AZD5004 Dose D once daily from Days 44-49, then single doses of AZD5004 Dose E once daily from Days 50-56. In Period 4, participants receive single dose of pioglitazone co-administered with single dose of AZD5004 Dose E on Day 57, followed by single doses of AZD5004 Dose E once daily from Days 58-63.

    Drug: AZD5004 · Drug: Pioglitazone

Interventions

  • AZD5004 will be administered orally.

  • Mitiglinide will be administered orally.

  • Pioglitazone will be administered orally.

06

What researchers measure

Primary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf)

    To assess the effect of AZD5004 on the PK (AUCinf) of mitiglinide and pioglitazone in healthy participants

    Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To assess the effect of AZD5004 on the PK (AUClast) of mitiglinide and pioglitazone in healthy participants

    Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70

  3. Maximum observed drug concentration (Cmax)

    To assess the effect of AZD5004 on the PK (Cmax) of mitiglinide and pioglitazone in healthy participants

    Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70

Secondary outcomes

  1. Number of participants with adverse events (AEs) and AE of special interest (AESI)

    To examine the safety and tolerability of AZD5004 alone and in combination with mitiglinide and pioglitazone in healthy participants

    Time frame: Part A: Up to follow-up visit [Day 54 (± 3 days)]; Part B: Up to follow-up visit [Day 74 (± 3 days)]

  2. Terminal elimination half-life (t½λz)

    To assess the effect of AZD5004 on the PK (t½λz) of mitiglinide and pioglitazone in healthy participants

    Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70

  3. Terminal rate constant (λz)

    To assess the effect of AZD5004 on the PK (λz) of mitiglinide and pioglitazone in healthy participants

    Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70

  4. Time to reach maximum observed concentration (tmax)

    To assess the effect of AZD5004 on the PK (tmax) of mitiglinide and pioglitazone in healthy participants

    Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70

  5. Part A: Ratio of mitiglinide + AZD5004 to mitiglinide (alone) based on AUCinf (RAUCinf)

    To assess the effect of AZD5004 on the PK (RAUCinf) of mitiglinide in healthy participants

    Time frame: From Day 1 to Day 50

  6. Part A: Ratio of mitiglinide + AZD5004 to mitiglinide (alone) based on AUClast (RAUClast)

    To assess the effect of AZD5004 on the PK (RAUClast) of mitiglinide in healthy participants

    Time frame: From Day 1 to Day 50

  7. Part A: Ratio of mitiglinide + AZD5004 to mitiglinide (alone) based on Cmax (RCmax)

    To assess the effect of AZD5004 on the PK (RCmax) of mitiglinide in healthy participants

    Time frame: From Day 1 to Day 50

  8. Part B: Ratio of pioglitazone + AZD5004 to pioglitazone (alone) based on AUCinf (RAUCinf)

    To assess the effect of AZD5004 on the PK (RAUCinf) of pioglitazone in healthy participants

    Time frame: From Day 1 to Day 70

  9. Part B: Ratio of pioglitazone + AZD5004 to pioglitazone (alone) based on AUClast (RAUClast)

    To assess the effect of AZD5004 on the PK (RAUClast) of pioglitazone in healthy participants

    Time frame: From Day 1 to Day 70

  10. Part B: Ratio of pioglitazone + AZD5004 to pioglitazone (alone) based on Cmax (RCmax)

    To assess the effect of AZD5004 on the PK (RCmax) of pioglitazone in healthy participants

    Time frame: From Day 1 to Day 70

07

Study locations

1 site
  • Research Site
    Fukuoka, 813-0017, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Jul 2026, 3 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 2, 2026
StartActual
Mar 13, 2026
Primary completionActual
Jul 2, 2026
CompletionActual
Jul 2, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07444424
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Mar 13, 2026
Primary completion
Jul 2, 2026
Completion
Jul 2, 2026
Last update
Jul 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elecoglipron · Mitiglinide · Pioglitazone

Start the discussion